Navjot Grewal
Sleep Medicine · San Ramon, CANPI 1245646231
Payments from drug & device makers
Across 43 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$257
- Avadel CNS Pharmaceuticals, LLC$237
- Vanda Pharmaceuticals Inc.$207
- Jazz Pharmaceuticals Inc.$126
- Merck$45
- Takeda Pharmaceuticals U.S.A., Inc.$43
- plus $161 from 7 others
What the payments were for
- Food & beverage$97691%
- Education$1009%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 8 | $257 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $237 |
| Vanda Pharmaceuticals Inc. | 10 | $207 |
| Jazz Pharmaceuticals Inc. | 7 | $126 |
| Merck | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $43 |
| Actelion Pharmaceuticals US, Inc. | 1 | $38 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Resmed Corp | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMRYZ$220
How this compares
$1,076 in reported general payments places this provider in the 45th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 85 | $1,340 |
| Doxepin Hcl | 11 | $1,176 |
| Eszopiclone | 18 | $836 |
| Trazodone Hcl | 90 | $728 |
| Mirtazapine | 45 | $523 |
| Gabapentin | 56 | $404 |
| Baclofen | 11 | $316 |
| Modafinil | 11 | $280 |
| Clonazepam | 15 | $30 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in San Ramon
- Haramandeep SinghSan Ramon$1.3M
- Jatinder MarwahaSan Ramon$4K
- Emmanuel MignotStanford$4.7M
- Daniel NormanLos Angeles$4.2M
- Atul MalhotraSan Diego$1.4M
- Lisa ShivesSan Diego$1.4M
- Logan SchneiderStanford$506K
- Tony MasriLos Gatos$327K
- Clete KushidaStanford$231K
- Sam KashaniSanta Monica$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.